Study To Evaluate The Efficacy And Safety Profile Of PF-06651600 And PF-06700841 In Subjects With Alopecia Areata
Status:
Completed
Trial end date:
2019-05-15
Target enrollment:
Participant gender:
Summary
This is a Phase 2a, randomized, double blind, parallel group, multicenter study with an
extension period. The study will have a maximum duration of approximately 113 weeks. This
includes an up to 5 weeks Screening Period, a 24 week Treatment Period, a 4 week Drug Holiday
(#1), an up to 12 month Single Blind (investigator open, sponsor open and subject blind)
Extension Period, a 4 week drug holiday (#2), a 6 month Cross Over Open Label Extension
Period and a 4 week Follow up Period.